TY - JOUR
T1 - Diabetes and overall survival among breast cancer patients in the U.S. Military Health System
AU - Shao, Stephanie
AU - Gill, Abegail A.
AU - Zahm, Shelia H.
AU - Jatoi, Ismail
AU - Shriver, Craig D.
AU - McGlynn, Katherine A.
AU - Zhu, Kangmin
N1 - Funding Information:
The authors thank the following individuals and institutes for their contributions to or support for the original data linkage project: Guy J. Garnett, David E. Radune, and Dr. Aliza Fink of ICF Macro; Wendy Funk, Julie Anne Mutersbaugh, Linda Cottrell, and Laura Hopkins of Kennel and Associates, Inc.; Kim Frazier, Dr. Elder Granger, and Dr. Thomas V. Williams of TMA; Annette Anderson, Dr. Patrice Robinson, and Dr. Chris Owner of the Armed Forces Institute of Pathology; Dr. Joseph F. Fraumeni Jr, Dr. Robert N. Hoover, Dr. Susan S. Devesa, and Gloria Gridley of the NCI; Dr. Lindsey Enewold, Dr. John Potter, Raul Parra, Anna Smith, Fiona Renalds, William Mahr, Hongyu Wu, Dr. Larry Maxwell, Miguel Buddle, and Virginia Van Horn of the United States Military Cancer Institute. The authors also thank Dr. Jie Lin for her help in conducting supplementary statistical analysis. This project was supported by the John P. Murtha Cancer Center, Walter Reed National Military Medical Center via the Uniformed Services University of the Health Sciences under the auspices of the Henry M. Jackson Foundation for the Advancement of Military Medicine and by the intramural research program of the NCI. The original data linkage was supported by the United States Military Cancer Institute and Division of Cancer Epidemiology and Genetics, NCI.
Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/1
Y1 - 2018/1
N2 - Background: Although research suggests that type II diabetes mellitus (DM-2) is associated with overall and breast cancer- specific decreased survival, most prior studies of breast cancer survival investigated the effect of preexisting DM-2 without assessing the effect of DM-2 diagnosed at or after breast cancer diagnosis. This study examined the relationship between DM-2 diagnosed before and after breast cancer diagnosis and overall survival. Methods: This study uses linked Department of Defense cancer registry and medical claims data from 9,398 women diagnosed with breast cancer between 1998 and 2007. Cox proportional hazards models were used to assess the association between DM-2 and overall survival. Results: Our analyses showed that women with DM-2 diagnosed before breast cancer diagnosis tended to have a higher risk of mortality compared with women without diabetes [HR = 1.17; 95% confidence interval (CI), 0.95-1.44] after adjustment for potential confounders. Similarly, patients diagnosed with DM-2 at or after breast cancer diagnosis had increased mortality compared with women without DM-2 (HR=1.39; 95% CI, 1.16-1.66). The similar tendency was also observed among most subgroups when results were stratified by race, menopausal status, obesity, tumor hormone receptor status, and stage. Conclusions: Using data from a health system that provides universal health care to its beneficiaries, this study showed an increased risk of death associated with DM-2, regardless of whether it was diagnosed before or at/after breast cancer diagnosis. Impact: These results suggest the potential effects of factors independent of the timing of DM-2 clinical diagnosis on the association of DM-2 with overall survival.
AB - Background: Although research suggests that type II diabetes mellitus (DM-2) is associated with overall and breast cancer- specific decreased survival, most prior studies of breast cancer survival investigated the effect of preexisting DM-2 without assessing the effect of DM-2 diagnosed at or after breast cancer diagnosis. This study examined the relationship between DM-2 diagnosed before and after breast cancer diagnosis and overall survival. Methods: This study uses linked Department of Defense cancer registry and medical claims data from 9,398 women diagnosed with breast cancer between 1998 and 2007. Cox proportional hazards models were used to assess the association between DM-2 and overall survival. Results: Our analyses showed that women with DM-2 diagnosed before breast cancer diagnosis tended to have a higher risk of mortality compared with women without diabetes [HR = 1.17; 95% confidence interval (CI), 0.95-1.44] after adjustment for potential confounders. Similarly, patients diagnosed with DM-2 at or after breast cancer diagnosis had increased mortality compared with women without DM-2 (HR=1.39; 95% CI, 1.16-1.66). The similar tendency was also observed among most subgroups when results were stratified by race, menopausal status, obesity, tumor hormone receptor status, and stage. Conclusions: Using data from a health system that provides universal health care to its beneficiaries, this study showed an increased risk of death associated with DM-2, regardless of whether it was diagnosed before or at/after breast cancer diagnosis. Impact: These results suggest the potential effects of factors independent of the timing of DM-2 clinical diagnosis on the association of DM-2 with overall survival.
UR - http://www.scopus.com/inward/record.url?scp=85040518710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040518710&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-17-0439
DO - 10.1158/1055-9965.EPI-17-0439
M3 - Article
C2 - 29097445
AN - SCOPUS:85040518710
SN - 1055-9965
VL - 27
SP - 50
EP - 57
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 1
ER -